Microdosed Atropine 0.1% and 0.01% Ophthalmic Solutions for Reduction of Pediatric Myopia Progression

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Myopia

In brief

This study evaluates the progression of myopia in participants using microdosed atropine 0.01%, atropine 0.1%, or placebo ophthalmic solution. Eligible subjects will administer study medication daily in each eye for 48 months. Efficacy and safety assessments will be performed at visits scheduled for 1, 6, 12, 18, 24, 30 and 36 months after initiation of medication use. Subjects will be re-randomized at the 36 month visit, then followed at 6 month intervals for an additional year.

Key facts

Study ID

NCT03942419

Run by

Eyenovia Inc.

People needed

438

Starts

2019-06-03

Expected to finish

2024-11-20

Last updated by the study team

2025-01-06

Who can join

Age: 3 and older, up to 12. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Refractive error by cycloplegic autorefraction: myopia -1.00 D to -6.00 D in both eyes; astigmatism ≤ 1.50 D in both eyes; anisometropia < 1.50 D.
• Best-corrected distance visual acuity in current correction of 0.2 logMAR or better with interocular difference ≤ 0.1 logMAR.
• Refractive correction for each eye meets the following criteria: myopia within ± 0.50 D of the manifest refraction at the Screening Visit; cylinder power within ± 0.50 D of the manifest refraction at the Screening Visit; when cylinder power is < 1.00 D, axis within ± 15 degrees of the manifest refraction; when cylinder power is ≥ 1.00 D, axis within ± 5 degrees of the manifest refraction.

You may not qualify if…

• Current or previous myopia treatment with non-study atropine, pirenzepine or other topical anti-muscarinic agent.
• Current use of bifocals, progressive-addition lenses, or multifocal soft contact lenses.
• Use of rigid gas permeable lenses, including orthokeratology lenses within 90 days of Screening.
• Known atropine allergy.
• Abnormality of the cornea, lens, central retina, iris or ciliary body.
• Current or prior history of manifest strabismus, amblyopia, or nystagmus.
• Prior eyelid, strabismus, intraocular, or refractive surgery.
• Intraocular pressure > 26 mmHg.
• History of premature birth by parent's report.
• Inability to perform protocol-prescribed testing due to preexisting neurological diagnoses, genetic syndrome, or other issues.
• Medical conditions predisposing patient to degenerative myopia, abnormal ocular refractive anatomy, and/or any history of intraocular surgery.
• Any systemic disease or condition that may affect visual function or development such as diabetes mellitus.
• Any ocular inflammation or external ocular inflammation within 30 days of Screening.
• History of punctal occlusion.
• Heterochromia.
• Lid squeezers.
• Participation in any study of an investigational, interventional product within 30 days prior to Screening Visit.
• Immediate family member of study staff designed to perform study evaluations or procedures.
• Pregnancy, or if sexually active, unwillingness to use an acceptable form of contraception during the study.
• Presence of a severe/serious ocular condition or any other unstable medical condition that, in the Investigator's opinion, may preclude study treatment or follow-up.

Where it is running

• University of Alabama at Birmingham School of Optometry — Birmingham, Alabama, United States
• Midwestern University — Glendale, Arizona, United States
• Canyon City Eyecare — Azusa, California, United States
• UC Berkeley — Berkeley, California, United States
• Marshall Ketchum University College of Optometry — Los Angeles, California, United States
• Ratner Children's Eye Center — San Diego, California, United States
• Illinois College of Optometry — Chicago, Illinois, United States
• Midwestern University — Downers Grove, Illinois, United States
• SUNY College of Optometry — New York, New York, United States
• Wake Forest Health Network Ophthalmology - Oak Hollow — High Point, North Carolina, United States
• Oculus Research — Raleigh, North Carolina, United States
• The Ohio State University - College of Optometry — Columbus, Ohio, United States
• Scott & Christie and Associates — Cranberry Township, Pennsylvania, United States
• Salus University - The Eye Institute — Philadelphia, Pennsylvania, United States
• Primary Eyecare Group — Brentwood, Tennessee, United States
• Southern College of Optometry — Memphis, Tennessee, United States
• Vanderbilt University Medical Center — Nashville, Tennessee, United States
• Virginia Pediatric Eye Center — Virginia Beach, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.